Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Iohexol
Drug ID BADD_D01180
Description Iohexol is an effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality.
Indications and Usage Iohexol ia used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures.
Marketing Status approved
ATC Code V08AB02
DrugBank ID DB01362
KEGG ID D01817
MeSH ID D007472
PubChem ID 3730
TTD Drug ID D02BLO
NDC Product Code 43228-100; 0407-1413; 71806-141; 0407-1414; 0407-1416; 0407-1415; 0407-1401; 0407-1411; 0407-1412; 65072-0801; 54702-501
UNII 4419T9MX03
Synonyms Iohexol | Iohexol 350 | Nycodenz | Compound 545 | Exypaque | Omnipaque
Chemical Information
Molecular Formula C19H26I3N3O9
CAS Registry Number 66108-95-0
SMILES CC(=O)N(CC(CO)O)C1=C(C(=C(C(=C1I)C(=O)NCC(CO)O)I)C(=O)NCC(CO)O)I
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Injection site reaction08.02.03.014; 12.07.03.0150.031299%
Injection site urticaria23.04.02.003; 10.01.06.003; 12.07.03.029; 08.02.03.029--Not Available
Insomnia19.02.01.002; 17.15.03.002--
Intestinal ischaemia24.04.08.001; 07.15.02.0010.007113%Not Available
Lacrimation disorder06.08.02.010--Not Available
Lacrimation increased06.08.02.0040.184237%
Laryngeal oedema10.01.05.003; 23.04.01.005; 22.04.02.0010.110258%
Laryngospasm22.04.02.0020.010670%
Leukocytosis01.02.01.0020.014227%
Lip oedema23.04.01.006; 10.01.05.004; 07.05.04.0040.028454%Not Available
Lip swelling23.04.01.007; 10.01.05.005; 07.05.04.0050.205577%Not Available
Livedo reticularis24.03.04.003; 23.06.05.0010.026320%Not Available
Loss of consciousness17.02.04.0040.300185%Not Available
Malaise08.01.01.0030.288804%
Meningism17.02.05.007--
Meningitis aseptic17.06.03.002; 11.01.03.002--Not Available
Meningitis bacterial17.06.10.002; 11.02.01.013--Not Available
Meningitis chemical17.06.03.003; 12.03.02.004--Not Available
Metastases to spine16.22.02.007; 15.09.03.0070.007113%Not Available
Micturition urgency20.02.02.0060.007113%
Moaning08.01.03.094; 19.04.02.011--Not Available
Mouth ulceration07.05.06.0040.021340%Not Available
Muscle contractions involuntary17.05.03.001; 15.05.03.0080.007113%Not Available
Muscle spasms15.05.03.004--
Muscle spasticity15.05.04.011; 17.05.03.007--
Muscle twitching15.05.03.0050.014227%Not Available
Muscular weakness17.05.03.005; 15.05.06.0010.066866%
Myalgia15.05.02.001--
Myelitis17.06.02.001; 11.01.03.007--
Myocardial ischaemia24.04.04.010; 02.02.02.008--Not Available
The 6th Page    First    Pre   6 7 8 9 10    Next   Last    Total 13 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene